Not all of these molecules in a hot bispecific niche are the same
Frothy or not, that’s the provocative question
If we were to describe the ever increasing PD(L)1 x VEGF landscape, I think a key word which comes to mind is ‘frothy’.
While a lot of folks are seeing this as a ‘hot’ emerging area of late, it’s all too easy to forget with the increasing variety of bispecifics and even trispecifics in this space comes risk.
Companies might be surfing the waves in phase 1/2 only to crash on the hidden rocks in later stage trials once we see data in Western populations.
In our latest landscape review we explore the ins and outs of 23 such molecules covering multiple permutations based on half a dozen different parameters. As always, there are some important learning points to be had because not all of the agents are exactly the same and companies love to spin their own angles or stories.
Perhaps not surprisingly, a number of red and green flags are already emerging from the depths…
To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.
This content is restricted to subscribers
